Walvax subsidiary gains Egyptian approval for 13-valent pneumococcal vaccine

Yunnan Walvax Biotechnology Co., Ltd. announced that its subsidiary, Yuxi Walvax Biotechnology Co., Ltd., has received a "Biologic Product Marketing Authorization" from the Egyptian Drug Authority (EDA) for its 13-valent pneumococcal polysaccharide conjugate vaccine. This approval marks the vaccine's official market entry in Egypt.

The 13-valent pneumococcal conjugate vaccine, approved for sale in China in 2020, is intended for infants and children aged 6 weeks to 5 years. It protects against infectious diseases caused by 13 serotypes of *Streptococcus pneumoniae*. Pneumococcal infections are a leading cause of death in children under five globally. *Streptococcus pneumoniae* is a common pathogen causing pneumonia and otitis media in Egyptian children.

This authorization is a crucial milestone in Walvax's internationalization strategy and establishes its presence in a key overseas market. Since 2018, Walvax has been a partner in Egypt's national immunization program, consistently supplying vaccine products. The company anticipates this marketing authorization will positively impact its future annual performance, though actual launch timing and sales performance in Egypt remain subject to uncertainties.